Definitive Contract 75F40124C00013
Award Date
12/6/23
Potential Completion Date
5/30/26
Potential Value
$2M
Federal Agency
Food and Drug Administration
Awardee
Emerald Innovations, Inc.
Ultimate Awardee
Not listed
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $811,126.00, was issued by the U.S. Food and Drug Administration (FDA) to Digital Medicine Society Inc., a non-profit organization based in Boston, Massachusetts. The contract was awarded under a Broad Agency Announcement (BAA) solicitation for research and development to support the FDA's regulatory science and innovation mission. The contract is a Definitive Contract with a Firm Fixed Price pricing type, and has an ultimate completion date of December 31,...
The Department of Health and Human Services Food and Drug Administration awarded a $19,824 purchase order to Mattek Corporation of Ashland, Massachusetts. The firm fixed price contract is for the delivery of melanoderm skin samples and maintenance media, specifically pigmented reconstructed dermis samples, from July 27, 2023 through November 30, 2023. As the prime contractor, Mattek Corporation will provide the requested products to support the FDA's research and regulatory activities. No...
The Department of Health and Human Services Food and Drug Administration awarded a $149,130 firm fixed price purchase order to Emulate Inc., doing business as Emulate, for the delivery of a CDER-2023-117371-ZOE MODULE (ZOE-CM2) WITH AN ORB HUB (ORB-HM1) MCMI23 - ROBUST ORGAN-ON-A-CHIP SYSTEM FOR BIOASSAY DEVELOPMENT. This award responds to Solicitation 75F40123Q00376 which sought a robust organ-on-a-chip system to support the FDA's bioassay development work. Place of performance will be...
The Food and Drug Administration (FDA) awarded a $48,680.00 firm fixed price purchase order to Emulate Inc., a for-profit small business, for the purchase of Emulate Chip-S1 Basic Research Kits. This contract supports the FDA's regulatory science initiatives and advances the agency's work on non-animal testing approaches. The award has an ultimate completion date of August 21, 2025. Emulate Inc. has previously received federal grants, including a cooperative agreement from the Defense Advanced...
This $4,714,475.00 definitive, firm-fixed-price federal contract was awarded by the U.S. Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to conduct research and development on mechanistic modeling and process analytical technology for exosome production. The work is being performed in Cambridge, Massachusetts and will be completed by September 29, 2026. This contract was competitively awarded and is not designated as a set-aside. The original solicitation...
This federal contract award, valued at $9,353.97, was issued by the Food and Drug Administration (FDA) to The Emmes Company LLC, a for-profit limited liability company that provides clinical research services. The contract is for clinical site monitoring in human subjects to evaluate the ability of dermal open flow microperfusion (DOFM) for bioequivalence testing of different diclofenac products at Joanneum Research in Graz, Austria. This is a firm fixed-price delivery order contract with an...
This is a $580,000.00 Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian agency, to F2G LTD, a for-profit organization based in the United Kingdom. The contract is for the creation and validation of a Patient Reported Outcome (PRO) instrument to assess the Health-Related Quality of Life (HRQOL) in patients with coccidioidomycosis. The period of performance has been extended to March 31, 2026. This contract was not set aside for any specific business...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $1,151,037 firm-fixed-price contract to the Regents of the University of Michigan for the development of "SEAMLESS DESIGN FOR MULTICOMPONENT ENDPOINTS FOR DRUG DEVELOPMENT IN RARE DISEASES." This definitive contract, which has a completion date of September 29, 2026, does not have a set-aside designation. The University of Michigan, a prominent U.S. state government-owned educational...
Landrau Scientific Innovations LLC was awarded a $567,980 firm fixed price definitive contract by the Department of Health and Human Services Food and Drug Administration to support the agency's Broad Agency Announcement PMQWP#237. This BAA seeks advanced research and development proposals to evaluate critical process parameters for the preparation of amphotericin B that influence toxicity, advancing the FDA's regulatory science and innovation goals. The prime contractor will conduct work at its...
The Department of Health and Human Services Food and Drug Administration awarded a $114 million firm fixed price delivery order contract to Harvard Pilgrim Health Care Inc. Office of Sponsored Programs Division. The contract is for the Sentinel Initiative-Operations Center and will utilize the prime contractor's expertise in data analytics and operations center management to support the FDA's post-market safety surveillance program through December 2024. Performance will take place in...